{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:16:06Z","timestamp":1791141366904,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The zeta-associated protein of 70 kDa (ZAP-70) is expressed in patients with aggressive chronic lymphocytic leukemia (CLL). We found that ZAP-70+ CLL cells expressed activated heat-shock protein 90 (Hsp90) with high binding affinity for Hsp90 inhibitors, such as 17-allyl-amino-demethoxy-geldanamycin (17-AAG), whereas normal lymphocytes or ZAP-70- CLL cells expressed nonactivated Hsp90. Activated Hsp90 bound and stabilized ZAP-70, which behaved like an Hsp90 client protein only in CLL cells. Treatment with Hsp90 inhibitors such as 17-AAG and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) induced ZAP-70 degradation and apoptosis in CLL cells but not in T cells, and also impaired B-cell receptor signaling in leukemia cells. Transduction of ZAP-70- CLL cells with an adenovirus encoding ZAP-70 activated Hsp90 and specifically rendered the leukemia cells sensitive to 17-AAG. These data indicate that Hsp90 is necessary for ZAP-70 expression and activity; that ZAP-70 is unique among Hsp90 clients, in that its chaperone-dependency is conditional on the cell type in which it is expressed; and also that ZAP-70 is required for cell survival and signaling in CLL. Additionally, ZAP-70 expression in CLL cells confers markedly heightened sensitivity to 17-AAG or 17-DMAG, suggesting that these or other Hsp90 inhibitors could be valuable therapeutically in patients with aggressive CLL. (Blood. 2005;106:2506-2512)<\/jats:p>","DOI":"10.1182\/blood-2005-03-1099","type":"journal-article","created":{"date-parts":[[2005,6,22]],"date-time":"2005-06-22T00:44:51Z","timestamp":1119401091000},"page":"2506-2512","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":100,"title":["ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"106","author":[{"given":"Januario E.","family":"Castro","sequence":"first","affiliation":[{"name":"From the Moores University of California San Diego (UCSD) Cancer Center, University of California; the Conforma Therapeutics Corporation; and the Chronic Lymphocytic Leukemia Research Consortium (CRC), San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Prada","sequence":"additional","affiliation":[{"name":"From the Moores University of California San Diego (UCSD) Cancer Center, University of California; the Conforma Therapeutics Corporation; and the Chronic Lymphocytic Leukemia Research Consortium (CRC), San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Loria","sequence":"additional","affiliation":[{"name":"From the Moores University of California San Diego (UCSD) Cancer Center, University of California; the Conforma Therapeutics Corporation; and the Chronic Lymphocytic Leukemia Research Consortium (CRC), San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeela","family":"Kamal","sequence":"additional","affiliation":[{"name":"From the Moores University of California San Diego (UCSD) Cancer Center, University of California; the Conforma Therapeutics Corporation; and the Chronic Lymphocytic Leukemia Research Consortium (CRC), San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguang","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Moores University of California San Diego (UCSD) Cancer Center, University of California; the Conforma Therapeutics Corporation; and the Chronic Lymphocytic Leukemia Research Consortium (CRC), San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Burrows","sequence":"additional","affiliation":[{"name":"From the Moores University of California San Diego (UCSD) Cancer Center, University of California; the Conforma Therapeutics Corporation; and the Chronic Lymphocytic Leukemia Research Consortium (CRC), San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"From the Moores University of California San Diego (UCSD) Cancer Center, University of California; the Conforma Therapeutics Corporation; and the Chronic Lymphocytic Leukemia Research Consortium (CRC), San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219414716900_REF1","doi-asserted-by":"crossref","unstructured":"Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program).2003: 153-175.","DOI":"10.1182\/asheducation-2003.1.153"},{"key":"2020021219414716900_REF2","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med.2001;194: 1639-1647.","DOI":"10.1084\/jem.194.11.1639"},{"key":"2020021219414716900_REF3","doi-asserted-by":"crossref","unstructured":"Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med.2004;351: 893-901.","DOI":"10.1056\/NEJMoa040857"},{"key":"2020021219414716900_REF4","doi-asserted-by":"crossref","unstructured":"Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther.2004;3: 1021-1030.","DOI":"10.1158\/1535-7163.1021.3.8"},{"key":"2020021219414716900_REF5","unstructured":"Ivy PS, Schoenfeldt M. Clinical trials referral resource: current clinical trials of 17-AG and 17-DMAG. Oncology (Huntingt).2004;18: 610,615,619-620."},{"key":"2020021219414716900_REF6","doi-asserted-by":"crossref","unstructured":"Xu W, Mimnaugh E, Rosser MF, et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem.2001;276: 3702-3708.","DOI":"10.1074\/jbc.M006864200"},{"key":"2020021219414716900_","doi-asserted-by":"crossref","unstructured":"Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A.2000;97: 10832-10837.","DOI":"10.1073\/pnas.170276797"},{"key":"2020021219414716900_REF8","unstructured":"An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ.2000;11: 355-360."},{"key":"2020021219414716900_REF9","unstructured":"Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene.1995;11: 933-939."},{"key":"2020021219414716900_REF10","doi-asserted-by":"crossref","unstructured":"Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets.2003;3: 301-323.","DOI":"10.2174\/1568009033481877"},{"key":"2020021219414716900_REF11","doi-asserted-by":"crossref","unstructured":"Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature.2003;425: 407-410.","DOI":"10.1038\/nature01913"},{"key":"2020021219414716900_","doi-asserted-by":"crossref","unstructured":"Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A.1994;91: 8324-8328.","DOI":"10.1073\/pnas.91.18.8324"},{"key":"2020021219414716900_","doi-asserted-by":"crossref","unstructured":"Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol.1998;143: 901-910.","DOI":"10.1083\/jcb.143.4.901"},{"key":"2020021219414716900_REF14","doi-asserted-by":"crossref","unstructured":"Tian ZQ, Liu Y, Zhang D, et al. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem.2004;12: 5317-5329.","DOI":"10.1016\/j.bmc.2004.07.053"},{"key":"2020021219414716900_REF15","doi-asserted-by":"crossref","unstructured":"Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest.1998;101: 1133-1141.","DOI":"10.1172\/JCI1472"},{"key":"2020021219414716900_REF16","doi-asserted-by":"crossref","unstructured":"Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A.2002;99: 3854-3859.","DOI":"10.1073\/pnas.022604399"},{"key":"2020021219414716900_REF17","doi-asserted-by":"crossref","unstructured":"Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell.1992;71: 649-662.","DOI":"10.1016\/0092-8674(92)90598-7"},{"key":"2020021219414716900_REF18","doi-asserted-by":"crossref","unstructured":"Cantwell MJ, Sharma S, Friedmann T, Kipps TJ. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood.1996;88: 4676-4683.","DOI":"10.1182\/blood.V88.12.4676.bloodjournal88124676"},{"key":"2020021219414716900_REF19","doi-asserted-by":"crossref","unstructured":"Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med.2003;348: 1764-1775.","DOI":"10.1056\/NEJMoa023143"},{"key":"2020021219414716900_REF20","doi-asserted-by":"crossref","unstructured":"Wegele H, Muller L, Buchner J. Hsp70 and Hsp90\u2014a relay team for protein folding. Rev Physiol Biochem Pharmacol.2004;151: 1-44.","DOI":"10.1007\/s10254-003-0021-1"},{"key":"2020021219414716900_REF21","doi-asserted-by":"crossref","unstructured":"Waxman L, Whitney M, Pollok BA, Kuo LC, Darke PL. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci U S A.2001;98: 13931-13935.","DOI":"10.1073\/pnas.241510898"},{"key":"2020021219414716900_REF22","doi-asserted-by":"crossref","unstructured":"Hu J, Flores D, Toft D, Wang X, Nguyen D. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol.2004;78: 13122-13131.","DOI":"10.1128\/JVI.78.23.13122-13131.2004"},{"key":"2020021219414716900_REF23","doi-asserted-by":"crossref","unstructured":"Guo Y, Guettouche T, Fenna M, et al. Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. J Biol Chem.2001;276: 45791-45799.","DOI":"10.1074\/jbc.M105931200"},{"key":"2020021219414716900_REF24","doi-asserted-by":"crossref","unstructured":"Jones DT, Addison E, North JM, et al. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. Blood.2004;103: 1855-1861.","DOI":"10.1182\/blood-2003-05-1603"},{"key":"2020021219414716900_REF25","doi-asserted-by":"crossref","unstructured":"George P, Bali P, Cohen P, et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res.2004;64: 3645-3652.","DOI":"10.1158\/0008-5472.CAN-04-0006"},{"key":"2020021219414716900_REF26","doi-asserted-by":"crossref","unstructured":"Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood.2004;105: 2036-2041.","DOI":"10.1182\/blood-2004-05-1715"},{"key":"2020021219414716900_REF27","doi-asserted-by":"crossref","unstructured":"Piatelli MJ, Doughty C, Chiles TC. Requirement for a hsp90 chaperone-dependent MEK1\/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes. J Biol Chem.2002;277: 12144-12150.","DOI":"10.1074\/jbc.M200102200"},{"key":"2020021219414716900_","doi-asserted-by":"crossref","unstructured":"Chen G, Cao P, Goeddel DV. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell.2002;9: 401-410.","DOI":"10.1016\/S1097-2765(02)00450-1"},{"key":"2020021219414716900_REF29","doi-asserted-by":"crossref","unstructured":"Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. Oncogene.2004;23: 5378-5386.","DOI":"10.1038\/sj.onc.1207705"},{"key":"2020021219414716900_REF30","doi-asserted-by":"crossref","unstructured":"Le Brazidec JY, Kamal A, Busch D, et al. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J Med Chem.2004;47: 3865-3873.","DOI":"10.1021\/jm0306125"},{"key":"2020021219414716900_REF31","doi-asserted-by":"crossref","unstructured":"Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature.1998;396: 336-342.","DOI":"10.1038\/24550"},{"key":"2020021219414716900_REF32","doi-asserted-by":"crossref","unstructured":"Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature.2002;417: 618-624.","DOI":"10.1038\/nature749"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/7\/2506\/1634929\/zh801905002506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/7\/2506\/1634929\/zh801905002506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:25:00Z","timestamp":1683120300000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/7\/2506\/21651\/ZAP70-is-a-novel-conditional-heat-shock-protein-90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-1099","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}